Emerging Proteomic Biomarkers UPP1 & AHSA1 in Pancreatic Cancer

Introduction to Pancreatic Cancer

Pancreatic cancer (PC) is among the deadliest malignancies, with a five-year survival rate lingering below 10%. Its incidence is climbing worldwide, and by 2030 PC is predicted to be the second leading cause of cancer-related deaths. Histologically, PC is classified into well-differentiated (WD), moderately differentiated (MD), and poorly differentiated (PD) tumors, with PD lesions demonstrating the greatest invasiveness and worst patient outcomes .

Mapping the Tumor Proteome

To uncover proteins that drive tumor development and aggressiveness, the authors applied a data-independent acquisition proteomics workflow to human pancreatic tumor samples and matched non-tumor tissues. They compared:

• Tumor vs. adjacent tissue: Five tumor/para-PC pairs (three PD, two MD).

• Poorly vs. moderately differentiated tumors: Eight PD-PC vs. seven MD-PC samples.

Using a timsTOF Pro mass spectrometer and DIA-NN software, they quantified thousands of proteins in each sample, then applied statistical filters (|log₂ fold-change|>0.263; P<0.05) to define differentially expressed proteins (DEPs) .

Discovery of Key Proteins: UPP1 and AHSA1

• Scope of proteomic remodeling:

  • 431 DEPs between tumors and adjacent tissue (332 upregulated, 99 downregulated).

  • 470 DEPs distinguishing PD from MD tumors.

• Shared signature: Five proteins were differentially expressed in both comparisons. Of these, Uridine Phosphorylase 1 (UPP1) and Activator of HSP90 ATPase Activity 1 (AHSA1) showed the most pronounced, stepwise increase in abundance from normal tissue → MD-PC → PD-PC .

Why UPP1 & AHSA1 Matter

• UPP1 regulates nucleotide salvage pathways and may fuel DNA synthesis in rapidly dividing cells.

• AHSA1 activates the HSP90 chaperone system, which stabilizes multiple oncogenic client proteins.

Their progressive overexpression suggests a direct link to tumor differentiation status and aggressiveness.

Validating the Proteomic Findings

The study reinforced its discovery phase with multiple validation steps:

1. In silico analysis using the GEPIA database confirmed that both UPP1 and AHSA1 transcripts are elevated in PC tumors versus normal pancreas.

2. RT-qPCR and Western blotting on an independent set of clinical specimens recapitulated the proteomic trends.

3. Immunohistochemistry (IHC) and immunofluorescence (IF) demonstrated intense staining of UPP1 and AHSA1 in tumor cells, particularly in poorly differentiated areas .

Together, these orthogonal approaches establish UPP1 and AHSA1 as robust markers of PC progression.

Implications for Diagnosis and Treatment

• Biomarker potential: Elevated UPP1 or AHSA1 levels in biopsy or blood-based assays could help stratify patients by tumor differentiation status, informing prognosis and treatment planning.

• Therapeutic targeting: Inhibitors of uridine phosphorylase or HSP90-chaperone function may preferentially impair aggressive, poorly differentiated tumors that rely on these pathways for growth and survival.

By linking specific proteomic alterations to phenotypic aggressiveness, this work paves the way for precision diagnostics and targeted therapies in a malignancy where new strategies are desperately needed.

Future Directions

The authors outline next steps to translate these findings into clinical impact:

1. Larger cohort validation to confirm biomarker performance across diverse patient populations.

2. Functional studies (e.g., gene knockdown or pharmacologic inhibition) in cell lines and animal models to establish causal roles for UPP1 and AHSA1 in tumor growth and metastasis.

3. Integration with other “omics” layers (genomics, metabolomics) to build a holistic view of tumor biology and uncover additional actionable vulnerabilities.

This study delivers the first comprehensive proteomic atlas linking protein expression patterns to pancreatic tumor differentiation, spotlighting UPP1 and AHSA1 as promising biomarkers and targets for the most aggressive forms of the disease.

The translation of the preceding English text in Chinese:

胰腺癌简介

胰腺癌（PC）是最致命的恶性肿瘤之一，五年生存率始终低于10%。其发病率在全球范围内持续上升，预计到2030年，胰腺癌将成为癌症相关死亡的第二大原因。从组织学上将胰腺癌分为高分化（WD）、中等分化（MD）和低分化（PD）三类，其中低分化病变侵袭性最强，患者预后最差。

肿瘤蛋白质组绘制

为了发现驱动肿瘤发生和进展的关键蛋白，研究者对人胰腺肿瘤样本及配对的非肿瘤组织应用了数据独立采集（DIA）蛋白质组学流程。比较内容包括：

• 肿瘤组织 vs. 邻近组织：5对肿瘤/邻近组织样本（3例PD，2例MD）。

• 低分化 vs. 中等分化肿瘤：8例PD-PC vs. 7例MD-PC。

研究者利用 timsTOF Pro 质谱仪和 DIA-NN 软件，对每个样本中成千上万的蛋白进行了定量，并通过统计筛选（|log₂倍数变化|>0.263；P<0.05）定义差异表达蛋白（DEPs）。

关键蛋白的发现：UPP1 与 AHSA1

蛋白组学重塑范围：

• 肿瘤与邻近组织间共检测出431个DEPs（332个上调，99个下调）。

• PD 与 MD 肿瘤间共检测出470个DEPs。

• 共有五种蛋白在两组比较中均差异表达，其中尿苷磷酸化酶1（UPP1）和HSP90 ATP酶活化因子1（AHSA1）在正常组织→MD-PC→PD-PC三级中呈现最显著且逐步上升的表达趋势。

UPP1 与 AHSA1 的意义

• UPP1 调控嘧啶核苷的救援途径，可能为快速分裂的肿瘤细胞提供DNA合成所需的底物。

• AHSA1 激活 HSP90 分子伴侣系统，可稳定多种促癌蛋白。

• 这两种蛋白的渐进性过度表达表明其与肿瘤分化状态及侵袭性密切相关。

蛋白组学结果的验证

研究在发现阶段基础上，进行了多种验证：

• 基于GEPIA数据库的生信分析确认，PC肿瘤中UPP1和AHSA1的转录本显著高于正常胰腺组织。

• 在另一批临床样本中，通过RT-qPCR和Western blot复现了蛋白组学的表达趋势。

• 免疫组化（IHC）与免疫荧光（IF）染色显示，UPP1和AHSA1在肿瘤细胞中，尤其是低分化区域，染色强度显著增强。

这些不同方法的交叉验证，确立了UPP1和AHSA1作为胰腺癌进展的稳健标志物。

诊断与治疗的启示

• 生物标志物潜力：在活检或血液检测中检测UPP1或AHSA1水平，可帮助评估肿瘤分化程度，指导预后判断和治疗决策。

• 治疗靶向：针对尿苷磷酸化酶或HSP90伴侣功能的抑制剂，可能优先抑制依赖这些通路的侵袭性低分化肿瘤细胞的生长与存活。

本研究将特定蛋白组学改变与肿瘤表型侵袭性相结合，为胰腺癌的精准诊断与靶向治疗开辟了新思路。

未来研究方向

研究者提出了将该发现转化为临床应用的下一步计划：

1. 扩大样本队列，以验证该生物标志物在不同患者群体中的表现。

2. 在细胞系和动物模型中，通过基因敲低或药物抑制，阐明UPP1和AHSA1在肿瘤生长及转移中的因果作用。

3. 与其他“组学”层面（基因组学、代谢组学）结合，构建肿瘤生物学的整体图谱，发现更多可操作的脆弱点。

该研究首次构建了一个全面的蛋白质组图谱，将蛋白表达模式与胰腺肿瘤的分化程度联系起来，突显了UPP1和AHSA1在最具侵袭性肿瘤形式中的潜在标志物和靶点价值。